Table 4 . Prevalence of the components of metabolic syndrome (MetS) in patients with NAFLD based on different criteria and sex .
| MetS components | Frequency (percentage) | 95% CI | Odds ratio | ||
| Men | Women | ||||
| Abdominal obesity (NCEP/ATPIII) | Yes | 56 (19.6) | 436 (74.9) | 0.0579-0.1159 | 0.0819 |
| No | 229 (80.4) | 146 (25.1) | |||
| Abdominal obesity (CCDMIA) | Yes | 149 (52.3) | 310 (53.3) | 0.7238-1.2768 | 0.9613 |
| No | 136 (47.7) | 272 (46.7) | |||
| Hyperglycemia (NCEP/ATPIII) | Yes | 56 (19.6) | 123 (21.1) | 0.6408-1.2995 | 0.9126 |
| No | 229 (80.4) | 459 (78.9) | |||
| Hyperglycemia (CCDMIA) | Yes | 113 (39.6) | 205 (35.2) | 0.9022-1.6179 | 1.2082 |
| No | 172 (60.4) | 377 (64.8) | |||
| Hypertriglyceridemia | Yes | 135 (50.9) | 435 (74.7) | 0.2587-0.476 | 0.3509 |
| No | 130 (49.1) | 147 (25.3) | |||
| Low HDL level | Yes | 115 (43.7) | 320 (55.0) | 0.4745-0.853 | 0.6362 |
| No | 148 (56.3) | 262 (45.0) | |||
| Hypertension | Yes | 103 (36.1) | 231 (39.7) | 0.6414-1.1529 | 0.8599 |
| No | 182 (63.9) | 351 (60.3) | |||
NCEP/ATP-III, National Cholesterol Education Program Adult Treatment Panel III; CCDMIA, Criteria for Clinical Diagnosis of MetS in Iranian Adults.